{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T14:27:04Z","timestamp":1770560824180,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaci.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T07:46:43Z","timestamp":1493797603000},"page":"1411-1421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Biologics and biomarkers for asthma, urticaria, and nasal polyposis"],"prefix":"10.1016","volume":"139","author":[{"given":"Thomas B.","family":"Casale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.03.006_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jaci.2016.03.010","article-title":"Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis\u2014PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology","volume":"137","author":"Muraro","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.anai.2016.05.016","article-title":"Characterization of asthma endotypes: implications for therapy","volume":"117","author":"Stokes","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jaci.2016.03.009","article-title":"Biomarkers in asthmatic patients: Has their time come to direct treatment?","volume":"137","author":"Berry","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2014.10.026","article-title":"Biomarker-based asthma phenotypes of corticosteroid response","volume":"135","author":"Cowan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib7","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib8","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2017.03.006_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib11","doi-asserted-by":"crossref","first-page":"AB1","DOI":"10.1016\/j.jaci.2014.12.937","article-title":"Estimated asthma exacerbation reduction from omalizumab in a severe eosinophilic asthma population","volume":"135","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1378\/chest.10-0128","article-title":"Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin-prick test results","volume":"139","author":"van den Berge","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2017.03.006_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2017.03.006_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaip.2014.10.010","article-title":"The use of anti-IgE therapy beyond allergic asthma","volume":"3","author":"Stokes","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.03.006_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.03.006_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2017.03.006_bib23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2017.03.006_bib24","doi-asserted-by":"crossref","first-page":"243ra85","DOI":"10.1126\/scitranslmed.3008961","article-title":"Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production","volume":"6","author":"Gauvreau","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12931-016-0347-2","article-title":"A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma","volume":"17","author":"Harris","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2017.03.006_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0091-6749(03)01861-X","article-title":"Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial","volume":"112","author":"Rosenwasser","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib28","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.03.006_bib29","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.03.006_bib30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2017.03.006_bib33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.03.006_bib35","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jaci.2016.02.018","article-title":"Asthma inflammatory phenotypes show differential microRNA expression in sputum","volume":"137","author":"Maes","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2017.03.006_bib38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","article-title":"Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial","volume":"4","author":"O'Byrne","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib39","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1164\/rccm.201405-0859PP","article-title":"IL-17 in severe asthma. Where do we stand?","volume":"190","author":"Chesn\u00e9","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib41","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaip.2016.07.015","article-title":"Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study","volume":"5","author":"Zeiger","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.03.006_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","article-title":"Biologic therapies targeting eosinophils: current status and future prospects","volume":"3","author":"Legrand","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.03.006_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib45","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/all.12708","article-title":"Treatment with anti-OX40L or anti-TSLP does not alter the frequency of T regulatory cells in allergic asthmatics","volume":"70","author":"Baatjes","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.03.006_bib46","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaoto.2016.0678","article-title":"Subcutaneous dupilumab and mometasone furoate nasal spray for chronic rhinosinusitis with polyps","volume":"142","author":"Schneider","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaci.2017.03.006_bib50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2017.03.006_bib51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1034\/j.1398-9995.2003.00110.x","article-title":"Enhanced Soluble Interleukin 5 Receptor alpha expression in nasal polyposis","volume":"58","author":"Gevaert","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.03.006_bib52","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.158.8.3902","article-title":"Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia","volume":"158","author":"Simon","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib53","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jaip.2015.04.008","article-title":"How omalizumab came to be studied as a therapy for chronic spontaneous\/idiopathic urticaria","volume":"3","author":"Kaplan","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.03.006_bib54","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1081-1206(10)60644-8","article-title":"Effect of omalizumab on patients with chronic urticaria","volume":"99","author":"Spector","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on h antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.03.006_bib60","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.03.006_bib61","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib62","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA(2) LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.03.006_bib63","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib64","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.jaci.2016.06.023","article-title":"A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria","volume":"138","author":"Harris","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib65","first-page":"25","article-title":"Role of biologics in intractable urticaria","volume":"9","author":"Cooke","year":"2015","journal-title":"Biologics"},{"key":"10.1016\/j.jaci.2017.03.006_bib66","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jaad.2009.10.043","article-title":"Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors","volume":"64","author":"Wilson","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.006_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/dth.12222","article-title":"Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients","volume":"28","author":"Sand","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2017.03.006_bib68","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00281-015-0491-7","article-title":"CAPS\u2014pathogenesis, presentation and treatment of an autoinflammatory disease","volume":"37","author":"Kuemmerle-Deschner","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2017.03.006_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/imt.14.106","article-title":"The inflammasome and IL-1\u03b2: implications for the treatment of inflammatory diseases","volume":"7","author":"Satoh","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaci.2017.03.006_bib70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2017.03.006_bib71","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/annrheumdis-2012-202192","article-title":"Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome","volume":"72","author":"de Koning","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.03.006_bib72","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.autrev.2014.08.031","article-title":"Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study","volume":"13","author":"N\u00e9el","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.03.006_bib73","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaci.2013.04.008","article-title":"Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study","volume":"132","author":"Krause","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib74","first-page":"237","article-title":"Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria","volume":"39","author":"Pereira","year":"2007","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib75","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0091-6749(99)70506-3","article-title":"Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria","volume":"103","author":"Hermes","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.006_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000058004","article-title":"Immune profiles of patients with chronic idiopathic urticaria","volume":"128","author":"Piconi","year":"2002","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917304803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917304803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:04:46Z","timestamp":1758791086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917304803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0091674917304803"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.03.006","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics and biomarkers for asthma, urticaria, and nasal polyposis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}